| abstract |
The present invention belongs to the field of pharmaceutical industry and relates to novel monoclonal antibodies and fragments thereof which are bound to the available surface of a human recombinant TNF-α, TNF-α analogues and TNF-α soluble receptors p55 and p75. Further, the invention relates to stable hybridoma cell lines, which lines are capable of producing such monoclonal antibodies, to a process for the preparation thereof and to pharmaceutical preparations containing them. The invention also relates to a method for the quantitative determination of human TNF-α, free or complexed with soluble TNF-α receptors p55 and p75, and to a kit used therefor. By hitherto disclosed monoclonal antibodies and reagents developed therefrom, it has not been possible to simultaneously determine free TNF-α and its soluble receptors p55 and p75 as well as complexes thereof. Another object of the invention is also the TNF-α analogue TNF-α Cys95His107His108Cys148, which in a complex with TNF-α soluble receptors, is used as an antigen for immunization of mice. |